The first thing you notice is the stillness. In a video from one of Multiply Labs's facilities, a multi-armed robotic cluster moves through a sequence of fluid transfers with quiet precision. There are no lab-coated technicians rushing between stations; the robot is performing a cell therapy manufacturing protocol. This is the company's core proposition: what if the most delicate, individualized work in medicine could be handed off to a machine that learned by watching?
Multiply Labs, founded in 2016 by MIT alumni Fred Parietti and Alice Melocchi, is building robotic biomanufacturing infrastructure. Its systems are modular, cloud-controlled robotic clusters designed to automate the sterile, high-throughput manufacturing steps for cell and gene therapies. The company started with a focus on personalized polypills [Forbes, 2019]. Today, Multiply Labs sells both the physical robotic systems and a companion software suite called Digital QC, which handles process planning, real-time sensor monitoring, and the creation of electronic batch records [Multiply Labs].
From personalized pills to industrial-scale cells
The promise of cell therapies is colliding with a manufacturing bottleneck. Each dose is a bespoke product, crafted from a single patient's biology. The process is labor-intensive, prone to human error, and expensive. Multiply Labs's bet is that robotics, guided by software that learns from human demonstrations (imitation learning), can bring the scale and consistency of industrial automation to this task [PERPLEXITY SONAR PRO BRIEF].
Their approach is to build the orchestration layer. The robotic clusters are designed to be compatible with market-leading GMP instruments, acting as the hands that move samples between incubators, centrifuges, and bioreactors [Multiply Labs]. The Digital QC software sits on top, creating a digital thread that tracks every action and measurement [Multiply Labs]. The vision is a "pharma robotics as a service" model, where Multiply Labs deploys these systems into customer facilities and sells robotic production capacity [Y Combinator].
The traction: blue-chip pharma as proof of concept
Multiply Labs has assembled a roster of partners including AstraZeneca, Legend Biotech, and Kyverna Therapeutics [Multiply Labs]. In 2025, Kyverna entered a pilot to use the technology for its CAR T candidate, KYV-102 [Multiply Labs, 2025]. An expanded collaboration with Thermo Fisher Scientific aims to integrate robotic technology with Thermo Fisher's instruments [Business Wire, 2024]. The company is also deploying systems at Stanford's Laboratory for Cell and Gene Medicine [Multiply Labs].
The company has raised approximately $41.3 million from institutional investors, including a $25 million Series A led by Casdin Capital in 2021 and an $11.1 million follow-on round in 2023 [The Pharma Letter]. Headcount has grown to approximately 67 employees as of early 2026 [LeadIQ, 2026].
| Role | Name | Background |
|---|---|---|
| CEO & Co-Founder | Fred Parietti, Ph.D. | MIT alum; leads company strategy and vision. |
| CSO & Co-Founder | Alice Melocchi | Associate Professor at Università degli Studi di Milano; provides scientific direction. |
Where the wheels could come off
The risks for Multiply Labs are not trivial:
- The integration marathon. Selling into Big Pharma is a complex sales cycle. The capital-intensive nature of building hardware means the company must manage its burn rate carefully.
- The black box of biology. Biological processes are variable; cells behave differently from donor to donor. The software must be intelligent enough to handle this variability.
- Regulatory acceptance. Regulators like the FDA will need to sign off on therapies manufactured primarily by robots.
- Competitive response. Established lab automation giants could develop similar systems, turning a first-mover advantage into a costly standards war.
Multiply Labs's answer is a focus on deep collaboration. By partnering with instrument makers like Thermo Fisher and research institutions like Stanford, they are embedding themselves in the existing ecosystem. Their use of NVIDIA's Isaac and Omniverse platforms for simulation and scaling suggests a commitment to building on industry-accepted tools [NVIDIA Blog].
The next twelve months
The coming year will be about converting pilots into scaled contracts. The collaborations with AstraZeneca, Kyverna, and Legend Biotech are the leading indicators. A public announcement of a full commercial deployment at any of these partners would be a watershed moment. The expansion in Italy will test the company's ability to manufacture its own systems at volume. Ultimately, Multiply Labs is proposing a new icon: the flawless, tireless robotic arm. Its success hinges on convincing an entire industry that for medicines built one cell at a time, the most human thing to do might be to let the machines take over.